Subsequent validation demonstrated that the anti-proliferation effect of tivantinib in non-small cell lung cancer (NSCLC) cells was mediated with its potent inhibition of GSK3α and β. The gene discussed is GSK3A; the disease is non-small cell lung carcinoma.